MMR-mutation and the resulting hypermutant phenotype have been associated with worse clinical outcomes in terms of more frequent and rapid recurrences, tumor progression, and patient death in IDH-mutant astrocytomas compared to grade-matched counterparts in many, but not all studies [17, 124, 179, 200, 209]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).